Sernova (TSE:SVA) Price Target Cut to C$1.50

Sernova (TSE:SVA) had its price target trimmed by Leede Financial from C$3.00 to C$1.50 in a research report sent to investors on Friday, BayStreet.CA reports. The firm currently has a speculative buy rating on the stock. Leede Financial also issued estimates for Sernova’s FY2027 earnings at ($0.02) EPS.

Sernova Price Performance

TSE:SVA opened at C$0.26 on Friday. The firm has a market cap of C$82.72 million, a price-to-earnings ratio of -1.96 and a beta of 1.38. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. The company’s 50-day moving average is C$0.27 and its two-hundred day moving average is C$0.37. Sernova has a 12-month low of C$0.20 and a 12-month high of C$0.83.

Sernova (TSE:SVA) last released its earnings results on Friday, June 14th. The company reported C($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C($0.03). Research analysts expect that Sernova will post -0.08 EPS for the current year.

Insider Transactions at Sernova

In other news, Director Steven Sangha sold 930,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of C$0.24, for a total transaction of C$223,200.00. Insiders have purchased a total of 359,600 shares of company stock worth $92,771 in the last three months. Company insiders own 12.98% of the company’s stock.

About Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.